A recent review evaluated the association between serious adverse events and FDA-authorized COVID-19 treatments. Tocilizumab, an interleukin 6 receptor antagonist, was found to be associated with an increased risk of neutropenia, particularly in hospitalized or immunocompromised patients. Convalescent plasma also showed potential risks in specific subgroups. The researchers emphasized the importance of continued postmarket safety surveillance for approved COVID-19 treatments.

Source: Open Forum Infectious Diseases